December 21, 2016 8:58pm
Upside momentum sputtered as traders bolted with “our” upside in their pocket
The stem, cell, gene and regenerative therapy (SCG&RT) sector opened negative, stayed negative at the mid-day and closed negative.
Pre-open indication’s tally: 2 hits (BLFS and KITE) and 2 miss (BLCM and PSTI <+$0.01>)
… Appreciation’s here today and gone tomorrow or by the next session …
There are two things that investors need - interpretation of news and translation of market realities concerning the SCG&RT sector to corroborate share pricing.
I answer one question; in which company should investors put, keep and commit their money!
I say today what others won't, so you can do what others can't!
U.S. equities fell slightly on Wednesday, with real estate lagging, as the Dow Jones industrial average failed to reach 20,000.
The NASDAQ closed DOWN -12.51 or -0.23% to 5,471.43 and the DOW closed DOWN -32.66 or -0.16% to 19,941.76.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was negative with an A/DL of 12/30 and 1 flat;
- The mid-day stayed negative with an A/DL of 10/32 and 1 flat;
- The closing bell continued negative with A/DL of 9/31 and 3 flats;
Henry’omics:
The stem, cell, gene and regenerative therapy (SCG&RT) sector opened negative, stayed negative at the mid-day and closed negative.
- From this morning’s investor’s letter, “The "Santa Claus Rally," which normally stimulates positive rebounds but, becomes a temporary profit for “our” universe and ultimately into a loss as traders sell into strength. “
“These last two weeks of 2016 could end-up being the just another terrible finish for the sector as compared with the period 1/4/16 through 12/5/16.”
- Reiterating, “I am NOT always right, but investors have always been able to count on … ME for sector intelligence, signal interpretation and straight talk and answers. Forget return on investment (ROI) and start thinking return on speculation!”
As the Hanukah and Christmas holidays approach expect trading volumes to DROP significantly, which may lead to volatile swings within the market.
The planes, trains and highways out of Boston have expanded as I came out of town – tonight as some marketplace collaborators are commencing their holiday vacation plans!
The iShares Russell 2000 (IWM) indicated a negative -0.26% in the pre- open and closed DOWN -0.65%; the iShares NASDAQ Biotechnology (IBB) did NOT indicate in the pre-open and closed DOWN -1.13%.
The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded lower near 11.3.
Today’s 3 biggest $ gainers included:
- Cellectis SA (CLLS) +$0.27 after Tuesday’s +$0.56;
- Capricor (CAPR) +$0.04
- Brainstorm (BCLI) +$0.02
Today’s 3 biggest $ losers of the session were:
- bluebird bio (BLUE) -$2.85;
- Spark Therapeutics (ONCE) -$2.73 after Tuesday’s +$1.74 after Monday’s -$2.13;
- Kite Pharma (KITE) -$2.49 after Tuesday’s +$0.75 after Monday’s -$1.13 after Friday’s+$2.49 after Thursday’s +$1.64 after last Wednesday’s +$1.02;
The downside trend reflects a pricing trend range of:
- Wednesday’s decliners ranged from – 0.20% <MESO> to –7.22% <KOOL) in 31 equities;
- Tuesday’s decliners ranged from -0.32% <CUR> to -28.35% <NWBO> in 15 equities;
- Monday’s decliners ranged from -14.69% <NWBO> to -0.48% <RGNX> in 20 equities;
- Friday’s decliners ranged from -0.07% <BLUE> to -19.36% <NWBO> in 26 equities;
- Thursday’s decliners ranged from -0.11% <MDXG> to -15.06% <NWBO>in 19 equities;
- Last Wednesday’s decliners ranged from -0.22% <MDXG> to- 7.36% <IMUC> in 26 equities;
The upside shows a pricing trend range of:
- Wednesday’s gainers ranged from +0.28% <VTGN> to +1.68% <CAPR> in 9 equities;
- Tuesday’s gainers ranged from +0.07% <BLUE> to +9.52 <ADVM>in 25 equities;
- Monday’s gainers ranged from +0.27% <ONVO> to +16.24% <CUR> in 22 equities:
- Friday’s gainers ranged from +0.09% <ONCE> to +10.42% <CYTX> in 14 equities;
- Thursday’s gainers ranged from +0.28% <VTGN> to +14.22% <BSTG> in 22 equities;
- Last Wednesday’s gainers ranged from +0.08% <ONCE> to +57.69% <VCEL> in 16 equities
Wrap-up: anybody can read a paragraph … review the percentage changes per day in the week of the decliners and advancers while …
- Wednesday’s 9 gainers slipped after Tuesday’s 25 following Monday’s 22 compared Friday’s 26
- Wednesday’s 31 decliners doubled after Tuesday’s 15 following Monday’s 20 compared to Friday’s 14 …
Pre-open indication’s tally: 2 hits (BLFS and KITE) and 2 miss (BLCM and PSTI)
- BioLife Solutions (BLFS) closed DOWN -$0.05 – hit;
- Bellicum Pharmaceuticals (BLCM) closed DOWN -$0.42 – miss;
- Kite Pharma (KITE) closed DOWN -$2.49 – hit;
- Pluristem (PSTI) closed DOWN - $0.01 – miss;
Percentage (%) decliners:
- Cesca therapeutics (KOOL) -7.22%;
- Caladrius Biosciences (CLBS) -5.83%;
- International Stem cell (ISCO) - $5.69;
- Juno therapeutics (JUNO) -5.65%;
- Regenxbio (RGNX) -5.33%
Percentage (%) advancers:
- Capricor (CAPR) +1.68%;
- Cellectis SA (CLLS) +1.58%;
- Histogenics (HSGX) +1.14%;
- Brainstorm (BCLI) +0.74% after Tuesday’s -6.60% after Monday’s +7.87% after Friday’s +7.06%;
- Fate therapeutics (FATE) +0.73%;
Flat:
- AxoGen (AXGN) at $8.65;
- Fibrocell (FCSC) at $0.74;
- Sangamo (SGMO) at $3.25
Review my fear gauge or the CBOE Volatility Index (VIX):
· Wednesday traded near 11.3;
· Tuesday traded near 11.5;
· Monday traded near 12;
· Friday traded near 12.2;
· Thursday traded near 12.7;
· Last Wednesday traded near 13.4;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.